TOGETHER WE CAN FIND A CURE

Let's Save the First Child from Duchenne muscular dystrophy

TOGETHER WE CAN FIND A CURE

Let's Save the First Child from Duchenne muscular dystrophy

Make a difference that lasts a lifetime!

Your donation of only 13¢ a day ($4/month) will help fund our clinical trial.

Make a difference that lasts a lifetime!

Your donation of only 13¢ a day ($4/month) will help fund our clinical trial.

PENNIES FOR HOPE

13 cents a day can save a child

Make a difference that lasts a lifetime!

Your donation of only 13¢ a day ($4/month) will help fund our clinical trial.

Make a difference that lasts a lifetime!

Your donation of only 13¢ a day ($4/month) will help fund our clinical trial.

TOGETHER WE CAN FIND A CURE

Let's Save the First Child from Duchenne muscular dystrophy

Make a difference that lasts a lifetime!

Your donation of only 13¢ a day ($4/month) will help fund our clinical trial.

Make a difference that lasts a lifetime!

Your donation of only 13¢ a day ($4/month) will help fund our clinical trial.

SIGN THE PETITION

The Jamesy Act-Activate SSI and Medicaid for DMD Patients Immediately

Sign the petition to demand immediate SSI and Medicaid access for children diagnosed with Duchenne muscular dystrophy—because families shouldn't have to wait while time runs out.

An Unforgettable Night of Flavor & Sound

SEPTEMBER 10, 2025

The TillingHouse at Suneagles Golf Club
2000 Lowther Dr., Eatontown, NJ 07724
VIP Admission: 5:30PM    |   General Admission: 6:00PM

Join us for the premier culinary event of the year, where top chefs, fine spirits, and live music come together under one roof.

GET TICKETS

JAR of Hope is on a mission to set a world record by assembling the largest group to perform 10 squats simultaneously—all in support of children battling Duchenne Muscular Dystrophy.


Why? Because children with Duchenne typically lose the ability to walk by age 12 and will never be able to rise from a chair again. This event is a powerful way to stand—literally and figuratively—with those who no longer can.

GET YOUR TICKETS!

Jersey Shore Blueclaws
August 7th, 2025 – 6:35pm
GET YOUR TICKETS

Because no child should have to suffer like this.

Duchenne muscular dystrophy (DMD) is one of the rarest diseases on Earth. DMD is a fatal, muscle-wasting disease you are born with. It occurs once in every 3,500 live births and effects mostly boys. In the United States, with a population of over 330,000,000 people, only about 20,000 children are stricken with Duchenne. And there is no cure.


Our goal is to find a cure for Duchenne muscular dystrophy. With organized fundraising events and support from you, we can continue our mission and turn the dream of finding a cure into a reality.

LEARN MORE

Together, JAR of Hope has

RAISED $7 MILLION+

HELPED OVER 25+ FAMILIES

SPREAD AWARENESS GLOBALLY

Together, JAR of Hope has

RAISED $7 MILLION+

HELPED OVER 25+ FAMILIES

SPREAD AWARENESS GLOBALLY

Duchenne Muscular Dystrophy Clinical Trial 

We have partnered with the University of Florida College of Medicine and RESTEM LLC to to initiate an important trial for Duchenne muscular dystrophy (DMD).


Authorization has been granted to begin Phase 1 of the trial. Here, a "randomized, double-blind, placebo-controlled Cross Over study to assess the safety, tolerability, and preliminary efficacy of Umbilical Cord Lining stem cells (ULSC) in Pediatric patients with Duchenne muscular dystrophy (DMD).”

LEARN MORE ABOUT THE TRIAL

In the News

July 31, 2025
🧬 What Happened FDA Request: On July 18, the FDA informally asked Sarepta to voluntarily halt all U.S. shipments of its Duchenne DMD gene therapy, Elevidys—a move driven by safety concerns after three patient deaths due to acute liver failure. This included two fatalities in teenage Duchenne patients treated with Elevidys and a third in an adult patient from a different Sarepta gene therapy trial . Initial Pushback: Sarepta initially resisted, stating there were no new safety concerns for ambulatory patients (those who can walk), and maintained shipments for that group. They had previously paused shipments for non-ambulatory patients earlier in the year after two deaths . Reversal and Pause: On July 21–22, Sarepta reversed course and voluntarily paused all shipments in the U.S. by end of business Tuesday, July 22, 2025, to cooperate with the FDA, respond to inquiries, and complete a revised safety labeling for Elevidys . --- 📌 Why It Matters Safety Labeling Update: The pause allows Sarepta and the FDA time to add a stricter warning (including a new black-box liver-risk warning) and possibly implement a Risk Evaluation and Mitigation Strategy (REMS) for monitoring liver safety . Regulatory Relations: CEO Doug Ingram labeled the decision “painful,” but necessary for maintaining a collaborative and constructive relationship with the FDA . Market Impact: Sarepta’s stock plunged, falling as much as 8–5% on the news, and is down nearly 90% year to date. Analysts warn that the pause and black-box warning could severely affect Elevidys uptake and 50–61% of Sarepta's revenue . --- 🔍 What’s Next Duration of Pause: The pause could extend 3–6 months while safety data is reviewed and label changes are finalized . Potential Outcomes: Resumption: Elevidys could return under new safety protocols/label. A REMS program may be required . Market Withdrawal: Analysts caution on the possibility of permanent withdrawal if FDA's safety concerns aren't resolved . Pipeline Impact: FDA has also placed a clinical hold on Sarepta’s other gene therapy trials (including for Limb-Girdle Muscular Dystrophy) and revoked platform tech designation due to the shared AAVrh74 viral vector . --- ✅ In Summary Key Takeaway Details Pause in effect All U.S. Elevidys shipments halted since end of business July 22 Why Safety concerns after 3 liver-related deaths from same viral vector Next steps Label update, FDA review, possible REMS; uncertain pause duration Risks Potential permanent withdrawal, impact on revenue, and pipeline delays
June 20, 2025
This article originally appeared on www.statnews.com , written by Christine McSherry—a registered nurse and founder of the Jett Foundation—on June 18, 2025.
June 5, 2025
Aluminum is the third most abundant element in the Earth's crust and has a wide range of industrial and household applications. However, increasing evidence suggests that aluminum exposure may pose health risks, particularly concerning brain health and toxicity. In this article, we’ll explore what aluminum is, how it affects our bodies—especially the brain—and how it may contribute to neurodegenerative diseases like Alzheimer’s. We’ll also discuss sources of aluminum exposure, methods of testing for toxicity, and natural approaches to detoxification. 
READ THE NEWS